These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 24432895)
1. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma? Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895 [TBL] [Abstract][Full Text] [Related]
2. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
3. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. Qiao W; Zhao J; Xing Y; Wang C; Wang T Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323 [TBL] [Abstract][Full Text] [Related]
7. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440 [TBL] [Abstract][Full Text] [Related]
8. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993 [TBL] [Abstract][Full Text] [Related]
9. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
12. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
14. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Adams HJ; Kwee TC Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352 [TBL] [Abstract][Full Text] [Related]
16. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772 [TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L; King N; Lechowicz MJ; Lonial S; Sinha R; Flowers CR Leuk Lymphoma; 2015 Feb; 56(2):383-9. PubMed ID: 24828864 [TBL] [Abstract][Full Text] [Related]
18. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884 [TBL] [Abstract][Full Text] [Related]
19. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729 [TBL] [Abstract][Full Text] [Related]
20. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]